News

UroToday1d
EAU 2025: Rapid-Fire Debate: How Radical Should a TURBT Be in MIBC? Only Diagnostic TURBT Is Sufficient
(UroToday.com) The 2025 EAU annual meeting featured a rapid-fire debate session on common problems and controversies in bladder cancer and a presentation by Dr. Marco Moschini contending that for ...
UroToday4d
ASCO 2025: Trials-in-Progress – a Randomized Phase 2 Study of the Efficacy and Safety of Stereotactic Body Radiation Therapy in Patients with Metastatic Urothelial Carcinoma ...
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers poster session.
UroToday1d
AUA 2025: Should Primary, Solitary, and Small (3 cm) TaHG Tumors Be Classified as Intermediate- or High-Risk Disease? A Retrospective, International Cohort Study
(UroToday.com) At the 2025 AUA Annual Meeting in Las Vegas, Dr. Jethro C.C. Kwong, from the University of Toronto, presented a retrospective international cohort study addressing a pressing ...
UroToday1d
AUA 2025: What Constitutes an Optimal TURBT in 2025?
(UroToday.com) The 2025 AUA annual meeting featured the 4 th annual IBCG Bladder Cancer Forum evaluating common problems and controversies in bladder cancer, moderated by Dr. William Tabayoyong, with ...
UroToday4d
ASCO 2025: Treatment Patterns and Survival by Race Among Men with mCRPC in the United States: A US Electronic Medical Record Database 2020-2023
(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Stephen Freedland discussing treatment patterns and survival by race among men with metastatic ...